F. Perez-ruiz et al., Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts, NEPHRON, 86(3), 2000, pp. 287-291
Aim: To evaluate the effect of nonsteroidal anti-inflammatory drug (NSAID)
withdrawal on renal function in patients with chronic gout after proper con
trol of hyperuricemia and gouty symptoms. Methods: Patients with chronic go
ut, who regularly used NSAIDs to control gouty symptoms prior to urate-lowe
ring therapy, were prospectively followed up in an observational study. Ris
k facto rs for renal function impairment were recorded, a nd the clearance
of creatinine (Ccr) was initially measured while on colchinine therapy to p
revent gouty bouts. Therapy with urate-lowering drugs was started in order
to keep serum urate levels under 6.0 mg/dl (275 mu mol/l), and the Ccr was
monitored during the follow-up period. Final assessment of the renal functi
on was made after 1 year free from gouty bouts and without NSAID therapy du
ring this period. Results: 87 patients completed a 1-year period of NSAID w
ithdrawal. Low initial Ccr was related to age, hypertension, hypertriglycer
idemia and the presence of previous renal diseases. After proper control of
gout and NSAID withdrawal during 1 year, the mean Ccr significantly raised
from 94 to 104 ml/min. The improvement was especially significant in patie
nts whose initial Ccr was under 80 ml/min. Their mean Ccr rose from 60 to 7
8 ml/min, and 12 of 29 patients achieved normal Ccr at the end of the study
. No risk factor correlated with improvement of the renal function. Conclus
ions: Renal function impairment in patients with chronic gout is mainly rel
ated to vascular risk factors, but improvement of the renal function was ob
served after proper control of hyperuricemia and NSAID withdrawal. Optimal
control of hyperuricemia and, therefore, of symptoms of gout should be espe
cially considered in patients with vascular risk factors in order to avoid
renal function loss due to NSAID use. Copyright (C) 2000 S. Karger AG, Base
l.